Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 534

1.

Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets.

Chen Z, Baz M, Lu J, Paskel M, Santos C, Subbarao K, Jin H, Matsuoka Y.

J Virol. 2014 Jun;88(12):7016-23. doi: 10.1128/JVI.00100-14. Epub 2014 Apr 9.

2.

A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys.

Min JY, Vogel L, Matsuoka Y, Lu B, Swayne D, Jin H, Kemble G, Subbarao K.

J Virol. 2010 Nov;84(22):11950-60. doi: 10.1128/JVI.01305-10. Epub 2010 Sep 1.

3.

Generation and Characterization of Live Attenuated Influenza A(H7N9) Candidate Vaccine Virus Based on Russian Donor of Attenuation.

Shcherbik S, Pearce N, Balish A, Jones J, Thor S, Davis CT, Pearce M, Tumpey T, Cureton D, Chen LM, Villanueva J, Bousse TL.

PLoS One. 2015 Sep 25;10(9):e0138951. doi: 10.1371/journal.pone.0138951. eCollection 2015.

4.
5.

Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.

Kamal RP, Blanchfield K, Belser JA, Music N, Tzeng WP, Holiday C, Burroughs A, Sun X, Maines TR, Levine MZ, York IA.

J Virol. 2017 Sep 27;91(20). pii: e01202-17. doi: 10.1128/JVI.01202-17. Print 2017 Oct 15.

6.

Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.

Chen GL, Lamirande EW, Cheng X, Torres-Velez F, Orandle M, Jin H, Kemble G, Subbarao K.

J Virol. 2014 Mar;88(5):2867-76. doi: 10.1128/JVI.01829-13. Epub 2013 Dec 26.

7.

H5 N-terminal β sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine.

Khurana S, Coyle EM, Verma S, King LR, Manischewitz J, Crevar CJ, Carter DM, Ross TM, Golding H.

Vaccine. 2014 Nov 12;32(48):6421-32. doi: 10.1016/j.vaccine.2014.09.049. Epub 2014 Oct 3.

PMID:
25284811
8.

Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs.

Ridenour C, Johnson A, Winne E, Hossain J, Mateu-Petit G, Balish A, Santana W, Kim T, Davis C, Cox NJ, Barr JR, Donis RO, Villanueva J, Williams TL, Chen LM.

Influenza Other Respir Viruses. 2015 Sep;9(5):263-70. doi: 10.1111/irv.12322.

9.

Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.

Boonnak K, Matsuoka Y, Wang W, Suguitan AL Jr, Chen Z, Paskel M, Baz M, Moore I, Jin H, Subbarao K.

J Virol. 2017 Jul 12;91(15). pii: e00547-17. doi: 10.1128/JVI.00547-17. Print 2017 Aug 1.

PMID:
28490598
10.

A live attenuated equine H3N8 influenza vaccine is highly immunogenic and efficacious in mice and ferrets.

Baz M, Paskel M, Matsuoka Y, Zengel J, Cheng X, Treanor JJ, Jin H, Subbarao K.

J Virol. 2015 Feb;89(3):1652-9. doi: 10.1128/JVI.02449-14. Epub 2014 Nov 19.

11.

Identification of critical residues in the hemagglutinin and neuraminidase of influenza virus H1N1pdm for vaccine virus replication in embryonated chicken eggs.

Wang W, Lu J, Cotter CR, Wen K, Jin H, Chen Z.

J Virol. 2013 Apr;87(8):4642-9. doi: 10.1128/JVI.03271-12. Epub 2013 Feb 13.

12.

A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets.

Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K.

Virology. 2008 Aug 15;378(1):123-32. doi: 10.1016/j.virol.2008.05.021. Epub 2008 Jun 27.

13.

A Single Dose of an Avian H3N8 Influenza Virus Vaccine Is Highly Immunogenic and Efficacious against a Recently Emerged Seal Influenza Virus in Mice and Ferrets.

Baz M, Paskel M, Matsuoka Y, Zengel JR, Cheng X, Treanor JJ, Jin H, Subbarao K.

J Virol. 2015 Jul;89(13):6907-17. doi: 10.1128/JVI.00280-15. Epub 2015 Apr 22.

14.

Development of a high-yield reassortant influenza vaccine virus derived from the A/Anhui/1/2013 (H7N9) strain.

Nakamura K, Shirakura M, Suzuki Y, Naito T, Fujisaki S, Tashiro M, Nobusawa E.

Vaccine. 2016 Jan 12;34(3):328-33. doi: 10.1016/j.vaccine.2015.11.050. Epub 2015 Dec 1.

PMID:
26657023
15.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

16.

Divergent H7 immunogens offer protection from H7N9 virus challenge.

Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P.

J Virol. 2014 Apr;88(8):3976-85. doi: 10.1128/JVI.03095-13. Epub 2014 Jan 22.

17.

Evaluation of live attenuated influenza a virus h6 vaccines in mice and ferrets.

Chen Z, Santos C, Aspelund A, Gillim-Ross L, Jin H, Kemble G, Subbarao K.

J Virol. 2009 Jan;83(1):65-72. doi: 10.1128/JVI.01775-08. Epub 2008 Oct 22.

18.

Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus.

Xu Q, Chen Z, Cheng X, Xu L, Jin H.

PLoS One. 2013 Oct 9;8(10):e76884. doi: 10.1371/journal.pone.0076884. eCollection 2013.

19.

Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Isakova-Sivak I, Chen LM, Bourgeois M, Matsuoka Y, Voeten JT, Heldens JG, van den Bosch H, Klimov A, Rudenko L, Cox NJ, Donis RO.

Clin Vaccine Immunol. 2014 May;21(5):722-31. doi: 10.1128/CVI.00819-13. Epub 2014 Mar 19.

Supplemental Content

Support Center